Literature DB >> 19535773

Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma.

Marie L De Bruin1, Lucille D A Dorresteijn, Mars B van't Veer, Augustinus D G Krol, Helena J van der Pal, Arnoud C Kappelle, Willem Boogerd, Berthe M P Aleman, Flora E van Leeuwen.   

Abstract

BACKGROUND: Information on clinically verified stroke and transient ischemic attack (TIA) following Hodgkin lymphoma is scarce. We quantified the long-term risk of cerebrovascular disease associated with the use of radiotherapy and chemotherapy in survivors of Hodgkin lymphoma and explored potential pathogenic mechanisms.
METHODS: We performed a retrospective cohort study among 2201 five-year survivors of Hodgkin lymphoma treated before age 51 between 1965 and 1995. We compared incidence rates of clinically verified stroke and TIA with those in the general population. We used multivariable Cox regression techniques to study treatment-related factors and other risk factors. All statistical tests were two-sided.
RESULTS: After a median follow-up of 17.5 years, 96 patients developed cerebrovascular disease (55 strokes, 31 TIAs, and 10 with both TIA and stroke; median age = 52 years). Most ischemic events were from large-artery atherosclerosis (36%) or cardioembolisms (24%). The standardized incidence ratio for stroke was 2.2 (95% confidence interval [CI] = 1.7 to 2.8), and for TIA, it was 3.1 (95% CI = 2.2 to 4.2). The risks remained elevated, compared with those in the general population, after prolonged follow-up. The cumulative incidence of ischemic stroke or TIA 30 years after Hodgkin lymphoma treatment was 7% (95% CI = 5% to 8%). Radiation to the neck and mediastinum was an independent risk factor for ischemic cerebrovascular disease (hazard ratio = 2.5, 95% CI = 1.1 to 5.6 vs without radiotherapy). Treatment with chemotherapy was not associated with an increased risk. Hypertension, diabetes mellitus, and hypercholesterolemia were associated with the occurrence of ischemic cerebrovascular disease, whereas smoking and overweight were not.
CONCLUSIONS: Patients treated for Hodgkin lymphoma experience a substantially increased risk of stroke and TIA, associated with radiation to the neck and mediastinum. Physicians should consider appropriate risk-reducing strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19535773     DOI: 10.1093/jnci/djp147

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  64 in total

Review 1.  Appropriate surveillance for late complications in patients in remission from Hodgkin lymphoma.

Authors:  Deborah L Darrington; Julie M Vose
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

Review 2.  State-of-the-art issues in Hodgkin's lymphoma survivorship.

Authors:  Shrujal S Baxi; Matthew J Matasar
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

3.  Recurrent stroke in childhood cancer survivors.

Authors:  Heather J Fullerton; Kayla Stratton; Sabine Mueller; Wendy W Leisenring; Greg T Armstrong; Rita E Weathers; Marilyn Stovall; Charles A Sklar; Robert E Goldsby; Les L Robison; Kevin R Krull
Journal:  Neurology       Date:  2015-08-26       Impact factor: 9.910

Review 4.  Second malignant neoplasms and cardiovascular disease following radiotherapy.

Authors:  Lois B Travis; Andrea K Ng; James M Allan; Ching-Hon Pui; Ann R Kennedy; X George Xu; James A Purdy; Kimberly Applegate; Joachim Yahalom; Louis S Constine; Ethel S Gilbert; John D Boice
Journal:  J Natl Cancer Inst       Date:  2012-02-06       Impact factor: 13.506

Review 5.  Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Authors:  Catherine S Diefenbach; Joseph M Connors; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lawrence Baizer; Andrew M Evens; Richard T Hoppe; Kara M Kelly; Daniel O Persky; Anas Younes; Lale Kostakaglu; Nancy L Bartlett
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 6.  Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors.

Authors:  Serhan Kupeli
Journal:  World J Cardiol       Date:  2014-07-26

Review 7.  Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy?

Authors:  Gregory M Cote; George P Canellos
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

8.  Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.

Authors:  Kuniaki Itoh; Tomohiro Kinoshita; Takashi Watanabe; Kenichi Yoshimura; Rumiko Okamoto; Takaaki Chou; Michinori Ogura; Masami Hirano; Hideki Asaoku; Mitsutoshi Kurosawa; Yoshiharu Maeda; Ken Omachi; Yukiyoshi Moriuchi; Masaharu Kasai; Kazunori Ohnishi; Nobuyuki Takayama; Yasuo Morishima; Kensei Tobinai; Harumi Kaba; Seiichiro Yamamoto; Haruhiko Fukuda; Masahiro Kikuchi; Tadashi Yoshino; Yoshihiro Matsuno; Tomomitsu Hotta; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2010-03-03       Impact factor: 2.490

Review 9.  The concept and evolution of involved site radiation therapy for lymphoma.

Authors:  Lena Specht; Joachim Yahalom
Journal:  Int J Clin Oncol       Date:  2015-07-07       Impact factor: 3.402

10.  Radiation exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data, 1950-2003.

Authors:  Yukiko Shimizu; Kazunori Kodama; Nobuo Nishi; Fumiyoshi Kasagi; Akihiko Suyama; Midori Soda; Eric J Grant; Hiromi Sugiyama; Ritsu Sakata; Hiroko Moriwaki; Mikiko Hayashi; Manami Konda; Roy E Shore
Journal:  BMJ       Date:  2010-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.